The primary patent for Humira (adalimumab) did not expire in 2016. According to DrugPatentWatch.com, the core composition of matter patent for Humira, U.S. Patent No. 6,096,722, expired on October 18, 2016 [1]. However, AbbVie, the manufacturer of Humira, had obtained numerous secondary patents covering manufacturing processes, methods of use, and formulations, which extended the drug's market exclusivity significantly beyond that date [1][2].
When did Humira's main patent protection actually end?
While the foundational patent for Humira's active ingredient expired in October 2016, AbbVie strategically secured a web of other patents. These secondary patents, related to specific manufacturing methods, dosages, and methods of treatment, were designed to prolong the drug's monopoly. This complex patent landscape meant that while one key patent concluded, the overall market exclusivity for Humira was maintained for several more years [1][2].
What happened after the primary patent expired?
Following the expiration of the 2016 patent, AbbVie continued to defend its market exclusivity through litigation against companies seeking to launch biosimilar versions of Humira. These legal battles often focused on the validity and applicability of the secondary patents. Despite the primary patent's expiration, AbbVie was able to prevent or delay the entry of biosimilars in the U.S. market until the later expiration of these later-expiring patents and the resolution of legal challenges [1][3].
When can biosimilar versions of Humira be legally sold?
The ability for biosimilar versions of Humira to enter the U.S. market has been contingent on the expiration or invalidation of AbbVie's secondary patents. For instance, AbbVie reached agreements with several biosimilar manufacturers, such as Amgen, Samsung Bioepis, and Boehringer Ingelheim, allowing their biosimilars to launch in the U.S. starting in 2023 [3]. This phased entry reflects the staggered expiration dates of the various patents protecting Humira [1].
How many patents protect Humira?
AbbVie's strategy involved obtaining a large number of patents related to Humira, reportedly over 100 patents in the U.S. alone. These patents covered various aspects, including the drug's chemical structure, manufacturing processes, methods of use for different autoimmune conditions, and formulations designed to improve efficacy or patient experience. This extensive patent portfolio was a key factor in extending Humira's market exclusivity [1][2].
Who are the main competitors for Humira biosimilars?
Several pharmaceutical companies have developed biosimilar versions of Humira, aiming to compete once market exclusivity allows. Notable competitors include Amgen with its product Amjevita, Samsung Bioepis with its product Hadlima, Boehringer Ingelheim with Cyltezo, and Sandoz with Hyrimoz, among others [3]. The introduction of these biosimilars is expected to increase competition and potentially lower prices for the treatment of various autoimmune diseases [1].
What is the current status of Humira patent litigation?
Humira has been the subject of extensive patent litigation, with AbbVie engaging in numerous legal disputes against biosimilar developers. These cases have often involved challenges to the validity of AbbVie's secondary patents and arguments about patent infringement. The outcomes of these litigations have significantly influenced the timelines for biosimilar market entry in different regions [1][3].
What is Humira used to treat?
Humira is a biologic medication approved for the treatment of several inflammatory autoimmune diseases. These include rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, plaque psoriasis, and hidradenitis suppurativa [2].
Sources:
1. https://drugpatentwatch.com/drugs/humira/
2. https://www.drugpatentwatch.com/media/news/humira-patent-expiry-and-biosimilar-competition
3. https://www.drugpatentwatch.com/news/amgen-announces-humira-biosimilar-launch-date